AR033984A1 - Derivados de pirrolidina, procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de medicamentos - Google Patents

Derivados de pirrolidina, procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de medicamentos

Info

Publication number
AR033984A1
AR033984A1 ARP010103416A ARP010103416A AR033984A1 AR 033984 A1 AR033984 A1 AR 033984A1 AR P010103416 A ARP010103416 A AR P010103416A AR P010103416 A ARP010103416 A AR P010103416A AR 033984 A1 AR033984 A1 AR 033984A1
Authority
AR
Argentina
Prior art keywords
arylcarbonyl
alkyl
arylalkyl
aryl
arylcarbonylalkyl
Prior art date
Application number
ARP010103416A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR033984A1 publication Critical patent/AR033984A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)

Abstract

Derivados de pirrolidina, que comprenden un compuesto de fórmula general (1) en donde R1 es hidrógeno, alquilcarbonilo o arilcarbonilo; R2 es alquilo, alquilcicloalquilo, alquilcicloalquilalquilo, cicloalquilo, halógenoalquilo, carboxialquilo, aminoalquilo, dialquilaminoalquilo, alcoxialquilo, alcoxicarbonilalquilo, alquinilo, arilo, arilalquilo, arilalquil(alcoxicarbonil)alquilo, arilcarbonilalquilo, ariloxialquilo, arilalquenilo, aril(alcoxicarbonil)alquilo, heteroarilo, heteroarilalquilo, heterociclilo o heterociclilalquilo; A es -C(O)-R3, -CH(OH)-R4, ó -C(O)-NR5R6, en donde R3 y R4 son independientemente del grupo formado por alquilo, arilo, arilalquinilo, arilalquilo y arilalquenilo; R5 es hidrógeno, alquilo, cicloalquilo, cicloalquilalquilo, carboxialquilo, o arilalquilo; R6 es alquilo, alquilcarbonilalquilo, cianoalquilo, hidroxialquilo, hidroxialquil-(hidroxialquilo), alcoxicarbonilalquilo, arilcarbonilalquilo, arilaminocarbonilalquilo, aril(alquil)aminocarbonil-alquilo, aminocarbonillaquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, cicloalquilo, cicloalquilalquilo, o carboxialquilo, o R6 se selecciona del grupo consistente en las fórmulas (2), (3) y (4) o -NR5R6 en -C(O)NR5R6 para A representa un anillo saturado de 5 o 6 miembros, sustituido opcionalmente con carboxi, alquiloxicarbonilo, hidroxi, alcoxicarbonilalcoxi, fenilalquilo o fenilalcoxicarbonilo, R7 es hidrógeno, alquilo, alquenilo, alquiltioalquilo, arilo, heteroarilo, carboxialquilo, carboxi, alcoxicarbonilalquilo, arilalquilo, o heteroarilalquilo; o un compuesto de fórmula 5, R7a es hidrógeno o alquilo; R8 es -OR9 o -NR10R11, en donde R9 es hidrógeno, alquilo, arilalquilo; R10 es hidrógeno o alquilo; y R11 es alquilo, arilo, heteroarilo, arilalquilo, o el grupo -NR10R11 representa un anillo de 5 ó 6 miembros opcionalmente sustituido con carboxi, alquiloxicarbonilo, hidroxi, alcoxicarbonilalcoxi, fenialaquilo o fenilalcoxicarbonilo; R12 es alquilo, arilo, o arilalquilo; Y es -O-, -O-S(O2)-, -O-C(O)- o -O-(C)-NH; m es 0, 1 o 2; X es -SO2, -CO-, -C(O)O-, -SO2NH-, o -C(O)NR13- en donde R13 es hidrógeno, alquilo, arilo o carboxialquilo; y formas diméricas, y/o ésteres farmacéuticamente aceptables, y/o sales farmacéuticamente aceptables, y/o sales farmacéuticamente aceptables de los mismos. Los compuestos son útiles como inhibidores de metaloproteasas, por ej. zinc proteasas, en particular zinc hidrolasas, y son efectivos en el tratamiento de enfermedades asociadas con la vasoconstricción de incidencia creciente. Se describen también un proceso para su preparación, composiciones farmacéuticas y el uso de dichos derivados para la fabricación de medicamentos para la profilaxis y tratamiento de trastornos que están causados por la actividad de la enzima conversora de endotelina (ECE), especialmente isquemia de miocardio, insuficiencia cardíaca congestiva, arritmia, hipertensión, hipertensión pulmonar, asma, vasoespasmo cerebral, hemorragia subaracnoidal, pre-eclampsia, enfermedades del rinón, aterosclerosis, enfermedad de Bueger, artritis de Takayasu, complicaciones diabéticas, cáncer de pulmón, cáncer prostático, trastornos gastroinstestinales, shock endotóxico y septicemia, y para la curación de heridas y control de la menstruación, glaucoma, rechazo de injertos, enfermedades asociadas con indicaciones citostáticas, oftalmológicas y cerebroprotectoras, y protección de órganos.
ARP010103416A 2000-07-19 2001-07-17 Derivados de pirrolidina, procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de medicamentos AR033984A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00114947 2000-07-19

Publications (1)

Publication Number Publication Date
AR033984A1 true AR033984A1 (es) 2004-01-21

Family

ID=8169224

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103416A AR033984A1 (es) 2000-07-19 2001-07-17 Derivados de pirrolidina, procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de medicamentos

Country Status (16)

Country Link
US (1) US6541638B2 (es)
EP (1) EP1303485A1 (es)
JP (1) JP4068452B2 (es)
KR (1) KR100568841B1 (es)
CN (1) CN1620433A (es)
AR (1) AR033984A1 (es)
AU (1) AU2001270627A1 (es)
BR (1) BR0112580A (es)
CA (1) CA2414311C (es)
GT (1) GT200100145A (es)
MX (1) MXPA03000223A (es)
PA (1) PA8522501A1 (es)
PE (1) PE20020294A1 (es)
UY (1) UY26847A1 (es)
WO (1) WO2002006222A1 (es)
ZA (1) ZA200300167B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000368A (es) * 2000-07-19 2004-09-13 Hoffmann La Roche Derivados de pirrolidina como inhibidores de metalproteasa.
JP4212358B2 (ja) 2000-12-28 2009-01-21 第一三共株式会社 Ｖｌａ−４阻害薬
EP1481967B1 (en) 2002-03-05 2011-05-04 Sumitomo Chemical Company, Limited Process for the preparation of biaryl compounds
WO2004089294A2 (en) 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
CA2521937A1 (en) 2003-04-10 2004-10-28 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
JP2006522835A (ja) 2003-04-10 2006-10-05 アムジェン インコーポレイテッド 環状アミン誘導体およびブラジキニンによって媒介される炎症関連障害の処置におけるそれらの使用
RU2006101541A (ru) 2003-06-20 2006-06-10 Амген Инк. (US) Производные пиперазина и способ их применения
JP4676884B2 (ja) 2003-07-24 2011-04-27 第一三共株式会社 シクロヘキサンカルボン酸類
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
KR20080111137A (ko) * 2006-04-13 2008-12-22 액테리온 파마슈티칼 리미티드 초기 단계 특발성 폐 섬유증을 위한 엔도텔린 수용체 대항제
ES2350548B1 (es) * 2009-06-25 2011-09-29 Institut Univ. De Ciència I Tecnologia, S.A. N-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
EP2730571A1 (en) * 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
JP7163916B2 (ja) * 2017-07-05 2022-11-01 日産化学株式会社 ベンジル化合物
CN110078593A (zh) * 2018-11-15 2019-08-02 南通正达农化有限公司 一种苹果蠹蛾性信息素的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
AU644008B2 (en) * 1990-08-10 1993-12-02 Sumitomo Pharmaceuticals Company, Limited Beta-lactam compounds, and their production and use
JP3091297B2 (ja) * 1992-01-10 2000-09-25 住友製薬株式会社 ピロリジン誘導体およびその製造方法
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
ATE226193T1 (de) * 1996-08-28 2002-11-15 Procter & Gamble Substituierte zyklische amine als metalloproteaseinhibitoren
AU736136B2 (en) * 1997-07-10 2001-07-26 Merck Sharp & Dohme Corp. Crystalline forms of antibiotic side chain intermediates
WO1999057121A1 (fr) * 1998-05-01 1999-11-11 Kyoto Pharmaceutical Industries, Ltd. Derives de carbapenem, son utilisation et composes intermediaires a base de carbapenem

Also Published As

Publication number Publication date
WO2002006222A1 (en) 2002-01-24
KR100568841B1 (ko) 2006-04-10
US20020049243A1 (en) 2002-04-25
GT200100145A (es) 2002-05-16
ZA200300167B (en) 2004-04-07
EP1303485A1 (en) 2003-04-23
JP4068452B2 (ja) 2008-03-26
PA8522501A1 (es) 2002-09-17
KR20030016416A (ko) 2003-02-26
PE20020294A1 (es) 2002-04-17
US6541638B2 (en) 2003-04-01
CA2414311C (en) 2008-01-08
MXPA03000223A (es) 2003-06-06
CA2414311A1 (en) 2002-01-24
JP2004504297A (ja) 2004-02-12
CN1620433A (zh) 2005-05-25
BR0112580A (pt) 2003-06-17
UY26847A1 (es) 2002-01-31
AU2001270627A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
AR033984A1 (es) Derivados de pirrolidina, procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de medicamentos
CA2927373C (en) Processes for preparing dihydropyrimidine derivatives and intermediates thereof
NO20073730L (no) Amidderivater
MY140729A (en) Amide derivatives
PL1678166T3 (pl) Inhibitory kinaz białkowych
JP2017512789A (ja) ジヒドロピリミジン化合物及び医薬におけるその適用
ATE404552T1 (de) Substituierte isochinolinderivate und anwendungsverfahren
WO2008076805B1 (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
NO20053748L (no) Pyrrolopyridazinderivater.
TW200635918A (en) Pharmaceutical compounds
TW200716643A (en) The preparation and use of compounds as protease inhibitors
KR20110002475A (ko) 치환 피리미딘-5-카르복시아미드 281
NZ543897A (en) Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
HUT67877A (en) Process for producing lactam peptides having hle inhibiting activity
TW200716541A (en) The preparation and use of compounds as protease inhibitors
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
MY129796A (en) Novel anti-inflammatory androstane derivatives
TNSN05188A1 (en) 4-aminopyrimidine-5-one
NO20061363L (no) Pyrazolo- og imidazo- pyrimidinderivater
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
PH12018500294A1 (en) 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
ATE357453T1 (de) Comt-inhibitoren

Legal Events

Date Code Title Description
FB Suspension of granting procedure